GV-backed cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Merck Group, Bristol Myers-Squibb and Novo-backed cancer drug developer Galecto has filed to go public weeks after it last funding round.

Novo remains the largest shareholder in the endocrine disorder drug developer, which went public in an upsized offering.

Z Corporation has exited its 40% stake in crypto trading exchange TaoTao in an acquisition by SBI.

Nanopareil employs nanofibre membranes to separate chemical compounds for the purposes of purifying biopharmaceutical candidates.

Big Hit Entertainment, the Netmarble-backed talent management agency and record company, priced its initial public offering at the top of its range.

Vector Capital is acquiring the data integration platform developer three years after NTT invested and five after it secured a $1bn valuation.

FM Global, Hearst Ventures and QBE Ventures are set to exit the insurance analysis software provider in an acquisition by Bold Penguin.

University of Wyoming-backed Momentus is set to merge with SPAC Stable Road Acquisition in a deal that values the space infrastructure company at $1.2bn.

McKesson Ventures was among the existing investors that provided $25m through a private placement that supported the deal between Augmedix and Malo Holdings.